<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329508</url>
  </required_header>
  <id_info>
    <org_study_id>P2B001/003</org_study_id>
    <nct_id>NCT03329508</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study With P2B001 in Subjects With Early Parkinson's</brief_title>
  <official_title>A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharma Two B Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharma Two B Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and&#xD;
      rasagiline, which are both approved drugs and routinely used in standard therapy for&#xD;
      Parkinson's disease. The two drugs work in two different mechanisms that help each other, so&#xD;
      there is a reason to believe that their combined activity will be better than each individual&#xD;
      drug, and that lower doses can be used without losing the therapeutic effect. Thus, the&#xD;
      development of P2B001 is intended to provide a combination of low doses of these two drugs,&#xD;
      in an improved formulation, that is hoped to be more effective in controlling Parkinson's&#xD;
      disease symptoms and with less side effects than each of the drugs taken alone or the current&#xD;
      available commercial drugs taken together. In a previously completed clinical trial a&#xD;
      significant improvement in Parkinson's disease symptoms was seen in patients treated with&#xD;
      P2B001 compared to patients that were treated with placebo.&#xD;
&#xD;
      In this phase 3 study , the safety and efficacy of P2B001 will be assessed by comparing&#xD;
      P2B001 to its individual components pramipexole and rasagiline. This will be done by&#xD;
      monitoring the motor and non-motor symptoms, evaluating responses participants provide on&#xD;
      questionnaires relating to Parkinson's disease and quality of life that will be completed on&#xD;
      every visit. In addition, this study will also compare P2B001 to a marketed drug of&#xD;
      pramipexole ER. Approximately 525 patients will participate in this research study and the&#xD;
      participation in this study will last between 14 to 18 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be&#xD;
      randomized to 4 treatment groups. Each subject will participate in the study for&#xD;
      approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2&#xD;
      weeks follow-up period. Subjects will be requested to take one capsule and 1-3 tablets of&#xD;
      study drug by mouth with a glass of water every day for 13 weeks. The study requires seven&#xD;
      visits to the clinic one every 2-4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in total Unified Parkinson's Disease Rating Scale (UPDRS) score (defined as sum of parts II and III, scores (0-160).</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Superiority of P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) score.</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Superiority of P2B 0.6/0.75 mg as compared to pramipexole ER in the change of Epworth Sleepiness Scale (ESS) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Total Parkinson's Disease Questionnaire 39 (PDQ39) score.</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The efficacy of P2B 0.6/0.75 mg as compared to its individual components in the change of Total PDQ39 score.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Early Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>P2B001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination once daily capsule of pramipexole and rasagiline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rasagiline capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rasagiline Once daily capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramipexole once daily capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole Extended Release</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2B001</intervention_name>
    <description>Fixed dose once daily combination capsule of pramipexole and rasagiline</description>
    <arm_group_label>P2B001</arm_group_label>
    <other_name>Fixed dose combination of Pramipexole and rasagiline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Rasagiline oral capsule</description>
    <arm_group_label>rasagiline capsule</arm_group_label>
    <other_name>rasagiline capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole low dose oral capsule</description>
    <arm_group_label>Pramipexole capsule</arm_group_label>
    <other_name>Pramipexole capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole ER</intervention_name>
    <description>Pramipexole ER titrated to optimal dose</description>
    <arm_group_label>Pramipexole Extended Release</arm_group_label>
    <other_name>Pramipexole Extended Release Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must&#xD;
             have bradykinesia with sequence effect. If rest tremor does not exist must have&#xD;
             prominent asymmetry of motor function.&#xD;
&#xD;
          2. Subject with disease duration less than 3 years since diagnosis.&#xD;
&#xD;
          3. Subject has a H&amp;Y stage score of &lt; 3.&#xD;
&#xD;
          4. Subject has a MMSE score ≥ 26.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism&#xD;
&#xD;
          2. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4&#xD;
             weeks; if previous exposure was less than 4 weeks then it must not be within 2 months&#xD;
             prior to the baseline visit.&#xD;
&#xD;
          3. Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if&#xD;
             previous exposure was less than 4 weeks then it must not be within 3 months prior to&#xD;
             the baseline visit.&#xD;
&#xD;
          4. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4&#xD;
             weeks; if previous exposure was less than 4 weeks then it must not be within 1 month&#xD;
             prior to the baseline visit.&#xD;
&#xD;
          5. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh&#xD;
             categorization C, score 10-15) hepatic impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pninit Litman</last_name>
    <role>Study Director</role>
    <affiliation>Pharma2b LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P2B001/003 Site Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 site Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Study site Englewood,</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Study Vernon</name>
      <address>
        <city>Vernon</city>
        <state>Connecticut</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Port Charlotte</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Honolulu</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site East Lansing</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site west Bloomfield</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Golden Valley</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site New Hampshire</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Camden</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Study site Edison</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 Study site Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Williamsville</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Asheville</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001 study site Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Hershey</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B0011/003 Study Veracity Neuroscience</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>p2B001/003 Study site Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Alexandria</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Kirkland</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Haag</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Haag</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Hanau</name>
      <address>
        <city>Hanau</city>
        <state>Hessen</state>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Bochum</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Dresden</name>
      <address>
        <city>Dresden</city>
        <state>SaACHSEN</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Gera Germany</name>
      <address>
        <city>Gera</city>
        <state>Thuringen</state>
        <zip>07551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Gera</name>
      <address>
        <city>Gera</city>
        <state>Thuringen</state>
        <zip>07551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Sant Cugat del Vallés</name>
      <address>
        <city>Sant Cugat del Vallés</city>
        <state>Barcelona</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Mostoles</name>
      <address>
        <city>Mostoles</city>
        <state>Madridid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Pamplona</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site La Paz</name>
      <address>
        <city>Madrid</city>
        <state>S</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Navarra Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 study site Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B0011/003 Study site HM Centro Integral de Neurociencias (CINAC)</name>
      <address>
        <city>Madrid</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Study site Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>early Parkinson's Disease</keyword>
  <keyword>Parkinson's diagnosis</keyword>
  <keyword>Parkinson's tretment</keyword>
  <keyword>Parkinson's medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

